Nucleic acid vaccines
- PMID: 7553573
- PMCID: PMC174632
- DOI: 10.1128/CMR.8.3.406
Nucleic acid vaccines
Abstract
The use of nucleic acid-based vaccines is a novel approach to immunization that elicits immune responses similar to those induced by live, attenuated vaccines. Administration of nucleic acid vaccines results in the endogenous generation of viral proteins with native conformation, glycosylation profiles, and other posttranslational modifications that mimic antigen produced during natural viral infection. Nucleic acid vaccines have been shown to elicit both antibody and cytotoxic T-lymphocyte responses to diverse protein antigens. Advantages of nucleic acid-based vaccines include the simplicity of the vector, the ease of delivery, the duration of expression, and, to date, the lack of evidence of integration. Further studies are needed to assess the feasibility, safety, and efficacy of this new and promising technology.
Similar articles
-
Co-immunization of mice with a retroviral DNA vaccine and GITRL-encoding plasmid augments vaccine-induced protection against retrovirus infection.Viral Immunol. 2008 Dec;21(4):459-67. doi: 10.1089/vim.2008.0046. Viral Immunol. 2008. PMID: 19115935
-
Antigenic variation during persistent lentivirus infections and its implications for vaccine development.Adv Exp Med Biol. 1989;251:251-72. doi: 10.1007/978-1-4757-2046-4_24. Adv Exp Med Biol. 1989. PMID: 2481964 Review. No abstract available.
-
Glycosylation as a key parameter in the design of nucleic acid vaccines.Curr Opin Struct Biol. 2022 Apr;73:102348. doi: 10.1016/j.sbi.2022.102348. Epub 2022 Mar 4. Curr Opin Struct Biol. 2022. PMID: 35255387 Free PMC article. Review.
-
Perspectives on retroviral pathogenesis and vaccines.AIDS Res Hum Retroviruses. 1996 Mar 20;12(5):465-7. doi: 10.1089/aid.1996.12.465. AIDS Res Hum Retroviruses. 1996. PMID: 8882335 Review. No abstract available.
-
Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery.Retrovirology. 2017 Feb 6;14(1):8. doi: 10.1186/s12977-017-0336-7. Retrovirology. 2017. PMID: 28166802 Free PMC article.
Cited by
-
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform.Vaccines (Basel). 2021 Feb 18;9(2):171. doi: 10.3390/vaccines9020171. Vaccines (Basel). 2021. PMID: 33670630 Free PMC article. Review.
-
Toward rational vaccine engineering.Adv Drug Deliv Rev. 2022 Apr;183:114142. doi: 10.1016/j.addr.2022.114142. Epub 2022 Feb 9. Adv Drug Deliv Rev. 2022. PMID: 35150769 Free PMC article. Review.
-
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA.Oncoimmunology. 2023 May 15;12(1):2212550. doi: 10.1080/2162402X.2023.2212550. eCollection 2023. Oncoimmunology. 2023. PMID: 37205983 Free PMC article.
-
COVID-19: Insights into Potential Vaccines.Microorganisms. 2021 Mar 15;9(3):605. doi: 10.3390/microorganisms9030605. Microorganisms. 2021. PMID: 33804162 Free PMC article. Review.
-
Nanoparticles and Antiviral Vaccines.Vaccines (Basel). 2023 Dec 27;12(1):30. doi: 10.3390/vaccines12010030. Vaccines (Basel). 2023. PMID: 38250843 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources